Why is survival after pembrolizumab affected by previous radiotherapy?

Lancet Oncol. 2017 Sep;18(9):e504. doi: 10.1016/S1470-2045(17)30472-2.

Authors

Farkhad Manapov¹, Olarn Roengvoraphoj², Chukwuka Eze²

Affiliations

¹ Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Munich 81377, Germany. Electronic address: farkhad.manapov@med.uni-muenchen.de.
² Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Munich 81377, Germany.

PMID: 28884692
DOI: 10.1016/S1470-2045(17)30472-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans
Melanoma*

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab